Endothelial Dysfunction Drives CRTd Outcome at 1-Year Follow-Up: A Novel Role as Biomarker for miR-130a-5p
暂无分享,去创建一个
G. Paolisso | R. Marfella | G. Signoriello | C. Mauro | G. Santulli | G. Savarese | C. Sardu | A. Ruocco | C. Sacra | M. Santamaria | M. Volpicelli | M. Trotta | M. D’Amico | Lorenza Marfella
[1] G. Santulli,et al. Aprocitentan: New insights , 2022, Frontiers in Cardiovascular Medicine.
[2] G. Paolisso,et al. Angiotensin receptor/Neprilysin inhibitor effects in CRTd non-responders: from epigenetic to clinical beside. , 2022, Pharmacological research.
[3] R. Marfella,et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry , 2022, Cardiovascular Diabetology.
[4] G. Santulli,et al. Glycation of ryanodine receptor in circulating lymphocytes predicts the response to cardiac resynchronization therapy. , 2021, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[5] L. Lund,et al. Cardiac resynchronization therapy with or without defibrillator in patients with heart failure , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[6] C. Israel,et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. , 2021, European heart journal.
[7] H. Bao,et al. MiR-130a regulating the biological function of colon cancer by targeting inhibition of PTEN. , 2020, European review for medical and pharmacological sciences.
[8] Jyun-Yi Du,et al. miRNA-130a improves cardiac function by down-regulating TNF-α expression in a rat model of heart failure. , 2018, European review for medical and pharmacological sciences.
[9] G. Paolisso,et al. Stretch, Injury and Inflammation Markers Evaluation to Predict Clinical Outcomes After Implantable Cardioverter Defibrillator Therapy in Heart Failure Patients With Metabolic Syndrome , 2018, Front. Physiol..
[10] G. Paolisso,et al. Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes , 2017, Cardiovascular Diabetology.
[11] P. Lawford,et al. Measures of endothelial dysfunction predict response to cardiac resynchronisation therapy , 2016, Open Heart.
[12] G. Paolisso,et al. Cardiac Resynchronization Therapy Outcomes in Type 2 Diabetic Patients: Role of MicroRNA Changes , 2015, Journal of diabetes research.
[13] D. Franco,et al. Negative Fgf8-Bmp2 feed-back is regulated by miR-130 during early cardiac specification. , 2015, Developmental biology.
[14] W. Kuebler,et al. The MicroRNA-130/301 Family Controls Vasoconstriction in Pulmonary Hypertension* , 2014, The Journal of Biological Chemistry.
[15] R. Marfella,et al. Impact of Diabetes Mellitus on the Clinical Response to Cardiac Resynchronization Therapy in Elderly People , 2014, Journal of Cardiovascular Translational Research.
[16] G. Paolisso,et al. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non‐responders , 2013, European journal of heart failure.
[17] F. Romeo,et al. Endothelial dysfunction is a marker of systemic response to the cardiac resynchronization therapy in heart failure. , 2013, Journal of cardiac failure.
[18] M. Rudin,et al. Loss of AngiomiR-126 and 130a in Angiogenic Early Outgrowth Cells From Patients With Chronic Heart Failure: Role for Impaired In Vivo Neovascularization and Cardiac Repair Capacity , 2012, Circulation.
[19] Thor Edvardsen,et al. Increased Levels of Inflammatory Cytokines and Endothelin-1 in Alveolar Macrophages from Patients with Chronic Heart Failure , 2012, PloS one.
[20] P. Ponikowski,et al. Identification of Chronic Heart Failure Patients with a High 12-Month Mortality Risk Using Biomarkers Including Plasma C-Terminal Pro-Endothelin-1 , 2011, PloS one.
[21] N. Varma,et al. Endothelial dysfunction in heart failure identifies responders to cardiac resynchronization therapy. , 2008, Heart rhythm.
[22] M. Iglarz,et al. Mechanisms of ET-1-induced Endothelial Dysfunction , 2007, Journal of cardiovascular pharmacology.
[23] Stijn van Dongen,et al. miRBase: microRNA sequences, targets and gene nomenclature , 2005, Nucleic Acids Res..
[24] E. Benjamin,et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. , 2002, Journal of the American College of Cardiology.
[25] D. Giannessi,et al. The role of endothelins and their receptors in heart failure. , 2001, Pharmacological research.